It has been announced that the collaboration between Summit Therapeutics and the University of Oxford working to develop Utrophin Modulators for the disorder DMD has been extended by 12 months.
It has been announced that the collaboration between Summit Therapeutics and the University of Oxford working to develop Utrophin Modulators for the disorder DMD has been extended by 12 months.